Show simple item record

dc.contributor.authorMartinez-Alonso, Emma
dc.contributor.authorAlcazar, Paula
dc.contributor.authorCamafeita, Emilio 
dc.contributor.authorFernandez-Lucas, Milagros
dc.contributor.authorRuiz-Roso, Gloria
dc.contributor.authorAlcazar, Alberto
dc.date.accessioned2021-01-08T16:25:25Z
dc.date.available2021-01-08T16:25:25Z
dc.date.issued2020-10-14
dc.identifier.citationSci Rep. 2020; 10(1):16029es_ES
dc.identifier.issn2045-2322
dc.identifier.urihttp://hdl.handle.net/20.500.12105/11592
dc.description.abstractA large proportion of end-stage renal disease (ESRD) patients under long-term haemodialysis, have persistent anaemia and require high doses of recombinant human erythropoietin (rhEPO). However, the underlying mechanisms of renal anaemia have not been fully elucidated in these patients. In this study, we will be focusing on anaemia and plasma proteins in ESRD patients on high-flux haemodialysis (HF) and on-line haemodiafiltration (HDF), to investigate using two proteomic approaches if patients undergoing these treatments develop differences in their plasma protein composition and how this could be related to their anaemia. The demographic and biochemical data revealed that HDF patients had lower anaemia and much lower rhEPO requirements than HF patients. Regarding their plasma proteomes, HDF patients had increased levels of a protein highly similar to serotransferrin, trypsin-1 and immunoglobulin heavy constant chain alpha-1, and lower levels of alpha-1 antitrypsin, transthyretin, apolipoproteins E and C-III, and haptoglobin-related protein. Lower transthyretin levels in HDF patients were further confirmed by transthyretin-peptide quantification and western blot detection. Since ESRD patients have increased transthyretin, a protein that can aggregate and inhibit transferrin endocytosis and erythropoiesis, our finding that HDF patients have lower transthyretin and lower anaemia suggests that the decrease in transthyretin plasma levels would allow an increase in transferrin endocytosis, contributing to erythropoiesis. Thus, transthyretin could be a critical actor for anaemia in ESRD patients and a novel player for haemodialysis adequacy.es_ES
dc.description.sponsorshipThis work was supported by Grants (to A.A.) from the Instituto de Salud Carlos III and cofinanced by the European Development Regional Fund (FEDER) (PI14/00705 and PI18/00255). E.M-A. is a recipient of a research.es_ES
dc.language.isoenges_ES
dc.publisherNature Researches_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleProteomic analysis of plasma proteins of high-flux haemodialysis and on-line haemodiafiltration patients reveals differences in transthyretin levels related with anaemia.es_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID32994444es_ES
dc.format.volume10es_ES
dc.format.number1es_ES
dc.format.page16029es_ES
dc.identifier.doi10.1038/s41598-020-72104-5es_ES
dc.contributor.funderInstituto de Salud Carlos III - ISCIII
dc.contributor.funderEuropean Regional Development Fund (ERDF/FEDER)
dc.description.peerreviewedes_ES
dc.relation.publisherversionhttps://doi.org/10.1038/s41598-020-72104-5es_ES
dc.identifier.journalScientific reportses_ES
dc.repisalud.orgCNICCNIC::Unidades técnicas::Proteómica / Metabolómicaes_ES
dc.repisalud.institucionCNICes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI14/00705es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI18/00255es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PTA2017-14093-Ies_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional